Catalyst Wire Dossier Catalyst Wire Dossier

recombinant SARS-CoV-2 fusion protein vaccine booster

null · Livzon Pharmaceutical Group Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for recombinant SARS-CoV-2 fusion protein vaccine booster, covering 2022-03-03 to 2022-03-03. Get the full timeline:

Most recent: Clinical Trial Update: Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity [Phase 2]

See pricing